TransCode Therapeutics, Inc. (RNAZ)
NASDAQ: RNAZ · Real-Time Price · USD
4.560
-0.690 (-13.14%)
At close: Jul 31, 2026, 4:00 PM EDT
4.940
+0.380 (8.33%)
After-hours: Jul 31, 2026, 7:46 PM EDT

TransCode Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-42.56-27.98-15.66-19.42-18.63-6.15
Net Income
-43.7-36.27-16.79-18.55-17.56-6.84
Earnings Per Share
-50.33-52.59-1336.63---
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
12.8417.815.812.774.9720.83
Total Debt
000.040.4500
Net Cash (Debt)
12.8417.815.772.324.9720.83
Net Cash Growth
10.95%208.58%149.15%-53.36%-76.14%-
Net Cash Per Share
14.6825.83459.69---

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-21.4-19.52-13.34-18.07-15.76-5.27
Capital Expenditures
--0.01-0.02-0.04-0.1-0.25
Free Cash Flow
-21.4-19.52-13.36-18.11-15.86-5.52
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.